Molecular physiology of natriuretic peptide signalling

被引:152
作者
Kuhn, M [1 ]
机构
[1] Univ Klinikum Munster, Inst Pharmacol & Toxicol, D-48149 Munster, Germany
关键词
natriuretic peptides; guanylyl cyclase; cyclic GMP;
D O I
10.1007/s00395-004-0460-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The natriuretic peptide family consists of three homologous members, atrial (ANP), B-type (BNP) and C-type natriuretic peptides (CNP). These small peptides activate specic membrane-bound guanylyl cyclase (GC) receptors (GC-A and GC-B), thus modulating cellular functions via the intracellular second messenger, cyclic GMP. Since the original discovery of cardiac ANP more than two decades ago, the application of gene targeting technology in mice has provided new valuable information regarding the molecular physiology and diverse biological functions of natriuretic peptides and their receptors. The GC-A and ANP gene knockouts demonstrated that this signalling system is not only essential in the maintenance of normal blood pressure and volume, but also has local, growth-moderating functions within the heart itself. Disruption of the genes encoding BNP, CNP or the CNP-receptor, GC-B, demonstrated that these "natriuretic peptides" are in fact unlikely to physiologically regulate renal sodium excretion but instead may exert important autocrine/paracrine cGMP-mediated effects on cellular proliferation and differentiation in different tissues. Notably, the intestinal peptide uroguanylin, which activates a third guanylyl cyclase (GC-C), exerts diuretic/natriuretic activity and links the intestine and kidney in an endocrine way to modulate renal function in response to oral salt load. Reviewed here is the physiology and biochemistry of natriuretic peptides and their guanylyl cyclase receptors, with special focus on the information gained to date from targeted disruption of specic members of this peptide family, their receptors, or effector molecules in the murine system.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 66 条
[1]  
AIRHART N, 2003, IN PRESS J BIOL CHEM
[2]   DIVERSE BIOLOGICAL ACTIONS OF ATRIAL-NATRIURETIC-PEPTIDE [J].
BRENNER, BM ;
BALLERMANN, BJ ;
GUNNING, ME ;
ZEIDEL, ML .
PHYSIOLOGICAL REVIEWS, 1990, 70 (03) :665-699
[3]   Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts [J].
Calderone, A ;
Thaik, CM ;
Takahashi, N ;
Chang, DLF ;
Colucci, WS .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :812-818
[4]   NATRIURETIC PEPTIDES INHIBIT DNA-SYNTHESIS IN CARDIAC FIBROBLASTS [J].
CAO, L ;
GARDNER, DG .
HYPERTENSION, 1995, 25 (02) :227-234
[5]   EVIDENCE FOR A SPLANCHNIC SODIUM INPUT MONITOR REGULATING RENAL SODIUM EXCRETION IN MAN - LACK OF DEPENDENCE UPON ALDOSTERONE [J].
CAREY, RM .
CIRCULATION RESEARCH, 1978, 43 (01) :19-23
[6]   Renal effects of uroguanylin and guanylin in vivo [J].
Carrithers, SL ;
Hill, MJ ;
Johnson, BR ;
O'Hara, SM ;
Jackson, BA ;
Ott, CE ;
Lorenz, J ;
Mann, EA ;
Giannella, RA ;
Forte, LR ;
Greenberg, RN .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 1999, 32 (11) :1337-1344
[7]   Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor [J].
Chauhan, SD ;
Nilsson, H ;
Ahluwalia, A ;
Hobbs, AJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (03) :1426-1431
[8]  
Chen HH, 1998, J CARDIOVASC PHARM, V32, pS22
[9]  
CHRISMAN T, 2003, 1 INT C CGMP LEIPZ
[10]   Dwarfism and early death in mice lacking C-type natriuretic peptide [J].
Chusho, H ;
Tamura, N ;
Ogawa, Y ;
Yasoda, A ;
Suda, M ;
Miyazawa, T ;
Nakamura, K ;
Nakao, K ;
Kurihara, T ;
Komatsu, Y ;
Itoh, H ;
Tanaka, K ;
Saito, Y ;
Katsuki, M ;
Nakao, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (07) :4016-4021